ArticlePakistan journal of medical sciences2026
Hand-Foot Syndrome as a Rare Side Effect of Bleomycin.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hand-Foot Syndrome is a rare adverse reaction to bleomycin-etoposide-cisplatin chemotherapy, characterized by acral skin desquamation, hyperpigmentation, and swelling involving the hands and feet. We report the case of a 32 years old Asian female, diagnosed with right-sided Stage-IV dysgerminoma, who developed cutaneous symptoms following the second cycle of chemotherapy. She presented with hyperpigmentation, swelling, and desquamation affecting both hands and feet. After consultation with the dermatology department, she was diagnosed with chemotherapy-induced skin toxicity. Bleomycin, along with other cytotoxic agents, was discontinued. Initiation of topical betamethasone therapy resulted in significant clinical improvement over the following weeks. One month after starting the treatment, her feet had healed completely, while her hands continued to improve in the recovery phase with ongoing supportive care. This case highlights a rare dermatologic complication of bleomycin-etoposide-cisplatin therapy, emphasizing the need for further exploration into its prevention and effective treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.